歌礼制药-B公布年度业绩 研发费用增加39.5%至约3.02亿元

格隆汇
26 Mar

格隆汇3月26日丨歌礼制药-B(01672.HK)公告,截至2024年12月31日止年度,集团的研发费用由上年度的约人民币216.8百万元增加39.5%至约人民币302.4百万元。集团的年内亏损由上年度的人民币144.7百万元增至人民币300.9百万元,主要由于肥胖症及其他代谢性疾病的研发开支增加。集团拥有充足的资金以支持其未来五年的创新研发。于报告期间及直至本公告日期,集团已就其代谢性疾病管线...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10